Extended Cox model for survival
| Covariate . | Coefficient estimate . | Effect . | P . |
|---|---|---|---|
| FAt [t < 104] [not inv(16) or t(8;21)] | 0.048 (0.007) | Quadratic | < .001 |
| Fat2 [t < 104] [not inv(16) or t(8;21)] | − 0.0006 (0.00009) | — | — |
| TAt [t < 104] | 0.055 (0.009) | Quadratic | < .001 |
| TAt2 [t < 104] | − 0.0007 (0.0001) | — | — |
| PS34 [t < 26] | 1.242 (0.120) | Negative | < .001 |
| PS34 [26 ≤ t < 52] | 0.682 (0.272) | Negative | .012 |
| PE [t < 26] | − 0.595 (0.104) | Positive | < .001 |
| Log WBC [t < 26] | 0.104 (0.033) | Higher worse | .002 |
| Log WBC [26 ≤ t < 78] | 0.255 (0.039) | Higher worse | < .001 |
| Age | 0.021 (0.002) | Older worse | < .001 |
| Inv(16) or t(8;21) | − 0.720 (0.193) | Positive | < .001 |
| Chromosome 5 and/or 7 abnormal | 0.731 (0.083) | Negative | < .001 |
| Other cytogenetic abnormalities | 0.235 (0.081) | Negative | .004 |
| Log duration of AHD | 0.095 (0.027) | Longer worse | < .001 |
| Log platelet count | − 0.165 (0.035) | Higher better | < .001 |
| Log serum bilirubin | 0.164 (0.070) | Higher worse | .018 |
| Covariate . | Coefficient estimate . | Effect . | P . |
|---|---|---|---|
| FAt [t < 104] [not inv(16) or t(8;21)] | 0.048 (0.007) | Quadratic | < .001 |
| Fat2 [t < 104] [not inv(16) or t(8;21)] | − 0.0006 (0.00009) | — | — |
| TAt [t < 104] | 0.055 (0.009) | Quadratic | < .001 |
| TAt2 [t < 104] | − 0.0007 (0.0001) | — | — |
| PS34 [t < 26] | 1.242 (0.120) | Negative | < .001 |
| PS34 [26 ≤ t < 52] | 0.682 (0.272) | Negative | .012 |
| PE [t < 26] | − 0.595 (0.104) | Positive | < .001 |
| Log WBC [t < 26] | 0.104 (0.033) | Higher worse | .002 |
| Log WBC [26 ≤ t < 78] | 0.255 (0.039) | Higher worse | < .001 |
| Age | 0.021 (0.002) | Older worse | < .001 |
| Inv(16) or t(8;21) | − 0.720 (0.193) | Positive | < .001 |
| Chromosome 5 and/or 7 abnormal | 0.731 (0.083) | Negative | < .001 |
| Other cytogenetic abnormalities | 0.235 (0.081) | Negative | .004 |
| Log duration of AHD | 0.095 (0.027) | Longer worse | < .001 |
| Log platelet count | − 0.165 (0.035) | Higher better | < .001 |
| Log serum bilirubin | 0.164 (0.070) | Higher worse | .018 |
FA = received fludarabine + ara-C regimen; t = weeks from start of treatment; [t < 104] = 1 if t < 104, 0 if t ≥ 104, etc; TA, received topotecan + ara-C regimen; PS, performance status; PE, protected environment; WBC, white blood cell; AHD, antecedent hematologic disorder.
Other variables considered for inclusion in the final model with TheP values obtained after adding each variable one at a time to the final model: acute myeloid leukemia (rather than myelodysplasia)P = .94, percentage of marrow blasts P= .10, hemoglobin P = .054.